NTHI

SEC filing NTHI Reports Q1 2026 Net Loss of $8.8M, $(0.38) EPS, vs $(1.78) EPS in Q1 2025

14d ago

Insider trade Purchase by Amir F Heshmatpour (President)

28d ago

Insider trade Purchase by Amir F Heshmatpour (President)

34d ago

Insider trade Purchase by Yousha Neman-Ebrahim (Chief Clinical Officer)

38d ago

Insider trade Purchase by Keithly Garnett (CFO)

38d ago

Insider trade Purchase by Amir F Heshmatpour (President)

38d ago

Insider trade Purchase by Amir F Heshmatpour (President)

39d ago

SEC filing NTHI Insider Purchases $300K; FY25 Net Loss $62M, $10.1M Cash Ops, NEO212 FDA Meeting In 4 Weeks, NEO100 Interim Data ~Aug 2026

46d ago

Insider trade Purchase by David Suh, JR. (Chief Accounting Officer)

49d ago

SEC filing NTHI Launches $75M ATM Equity Program, 3% Commission, Up to $75M Shares Offered via BTIG & A.G.P.

52d ago

Insider trade Purchase by Amir F Heshmatpour (President)

52d ago

Insider trade Purchase by Amir F Heshmatpour (President)

53d ago

Insider trade Purchase by Amir F Heshmatpour (President)

56d ago

SEC filing NTHI Raises $11.45M via 3 Private Placements, Issues $7.20 Shares & $9 Warrants, Net Proceeds for Working Capital

70d ago

SEC filing NTHI Announces NEO212 Phase 1 Dose Escalation Results, RP2D 610 mg, Phase 2 Initiation, FDA Type B Meeting Requested

87d ago

SEC filing NTHI Settles Dispute with Fox Infused for $600K Plus $137.9K Interest, Totaling $737,920.77

89d ago

Scanner Unusual volume (4.7x average)

124d ago

News NeOnc Technologies' Subsidiary, NuroMENA, Signs Master Services Agreement with M42’s IROS and Expands Board of Directors

153d ago